MX2014006272A - Anticuerpos anti-cd98 y metodos de uso de los mismos. - Google Patents
Anticuerpos anti-cd98 y metodos de uso de los mismos.Info
- Publication number
- MX2014006272A MX2014006272A MX2014006272A MX2014006272A MX2014006272A MX 2014006272 A MX2014006272 A MX 2014006272A MX 2014006272 A MX2014006272 A MX 2014006272A MX 2014006272 A MX2014006272 A MX 2014006272A MX 2014006272 A MX2014006272 A MX 2014006272A
- Authority
- MX
- Mexico
- Prior art keywords
- antibody
- seq
- human
- functional fragment
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161563443P | 2011-11-23 | 2011-11-23 | |
PCT/US2012/066347 WO2013078377A1 (en) | 2011-11-23 | 2012-11-21 | Anti-cd98 antibodies and methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2014006272A true MX2014006272A (es) | 2014-10-24 |
Family
ID=47295209
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2014006272A MX2014006272A (es) | 2011-11-23 | 2012-11-21 | Anticuerpos anti-cd98 y metodos de uso de los mismos. |
Country Status (15)
Country | Link |
---|---|
EP (1) | EP2782935A1 (pt) |
JP (1) | JP2015501639A (pt) |
KR (1) | KR20140125351A (pt) |
CN (1) | CN104302669A (pt) |
AU (1) | AU2012340623A1 (pt) |
BR (1) | BR112014012590A8 (pt) |
CA (1) | CA2856873A1 (pt) |
HK (1) | HK1202877A1 (pt) |
IL (1) | IL232755A0 (pt) |
MX (1) | MX2014006272A (pt) |
PH (1) | PH12014501164A1 (pt) |
RU (1) | RU2014124530A (pt) |
SG (1) | SG11201402619VA (pt) |
WO (1) | WO2013078377A1 (pt) |
ZA (1) | ZA201403760B (pt) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2634098T3 (es) | 2011-01-14 | 2017-09-26 | The Regents Of The University Of California | Anticuerpos terapéuticos contra la proteína ROR-1 y procedimientos para el uso de los mismos. |
WO2014197866A1 (en) | 2013-06-06 | 2014-12-11 | Igenica Biotherapeutics, Inc. | Modified antibodies and related compounds, compositions, and methods of use |
WO2014197871A2 (en) * | 2013-06-06 | 2014-12-11 | Igenica Biotherapeutics, Inc. | Antibody-drug conjugates, compositions and methods of use |
JP2017114763A (ja) * | 2014-03-26 | 2017-06-29 | 第一三共株式会社 | 抗cd98抗体−薬物コンジュゲート |
BR112017011234A2 (pt) * | 2014-12-10 | 2018-03-27 | Genentech Inc | anticorpos contra receptor da barreira hematoencefálica e métodos de uso |
DK3336185T3 (en) * | 2015-08-10 | 2022-01-24 | Univ Osaka | Antistof |
CN105385694B (zh) * | 2015-11-20 | 2019-01-18 | 中国人民解放军第四军医大学 | 抗人cd98单克隆抗体98-3h3轻、重链可变区基因及其应用 |
CN109562168A (zh) * | 2016-06-08 | 2019-04-02 | 艾伯维公司 | 抗cd98抗体及抗体药物偶联物 |
WO2017214456A1 (en) * | 2016-06-08 | 2017-12-14 | Abbvie Inc. | Anti-cd98 antibodies and antibody drug conjugates |
WO2017214462A2 (en) * | 2016-06-08 | 2017-12-14 | Abbvie Inc. | Anti-cd98 antibodies and antibody drug conjugates |
RS61828B1 (sr) | 2016-06-08 | 2021-06-30 | Abbvie Inc | Anti-b7-h3 antitela i antitelske konjugacije lekova |
KR20200118151A (ko) | 2018-02-07 | 2020-10-14 | 리제너론 파마슈티칼스 인코포레이티드 | 치료 단백질 전달을 위한 방법 및 조성물 |
EP3715370A1 (en) * | 2019-03-28 | 2020-09-30 | Technische Universität München | High affinity anticalins directed against human cd98hc |
US20230174669A1 (en) * | 2020-04-08 | 2023-06-08 | Aliada Therapeutics, Inc. | Anti-CD98 Antibodies And Uses Thereof |
AR124681A1 (es) | 2021-01-20 | 2023-04-26 | Abbvie Inc | Conjugados anticuerpo-fármaco anti-egfr |
CN117561276A (zh) * | 2021-06-02 | 2024-02-13 | 华辉安健(北京)生物科技有限公司 | 抗cd98抗体及其应用 |
AU2022401024A1 (en) | 2021-11-30 | 2024-05-16 | Daiichi Sankyo Company, Limited | Protease-cleavable masked antibodies |
CN115772541A (zh) * | 2021-12-17 | 2023-03-10 | 百奥赛图江苏基因生物技术有限公司 | Cd98hc基因人源化非人动物的构建方法及应用 |
Family Cites Families (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3720760A (en) | 1968-09-06 | 1973-03-13 | Pharmacia Ab | Method for determining the presence of reagin-immunoglobulins(reagin-ig)directed against certain allergens,in aqueous samples |
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
NZ207394A (en) | 1983-03-08 | 1987-03-06 | Commw Serum Lab Commission | Detecting or determining sequence of amino acids |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
ATE243754T1 (de) | 1987-05-21 | 2003-07-15 | Micromet Ag | Multifunktionelle proteine mit vorbestimmter zielsetzung |
US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
DE69129154T2 (de) | 1990-12-03 | 1998-08-20 | Genentech Inc | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
EP0605522B1 (en) | 1991-09-23 | 1999-06-23 | Medical Research Council | Methods for the production of humanized antibodies |
US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
NL9101953A (nl) | 1991-11-21 | 1993-06-16 | Seed Capital Investments | Testinrichting omvattende een plaat met een veelvoud van putjes met een bijbehorende doseerinrichting, alsmede een kit die deze inrichtingen omvat en toepassing van de inrichtingen. |
DE69233528T2 (de) | 1991-11-25 | 2006-03-16 | Enzon, Inc. | Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen |
WO1993016185A2 (en) | 1992-02-06 | 1993-08-19 | Creative Biomolecules, Inc. | Biosynthetic binding protein for cancer marker |
ZA932522B (en) | 1992-04-10 | 1993-12-20 | Res Dev Foundation | Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens |
GB9225453D0 (en) | 1992-12-04 | 1993-01-27 | Medical Res Council | Binding proteins |
AU690528B2 (en) | 1992-12-04 | 1998-04-30 | Medical Research Council | Multivalent and multispecific binding proteins, their manufacture and use |
US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
GB9701425D0 (en) | 1997-01-24 | 1997-03-12 | Bioinvent Int Ab | A method for in vitro molecular evolution of protein function |
US5994071A (en) | 1997-04-04 | 1999-11-30 | Albany Medical College | Assessment of prostate cancer |
US6602677B1 (en) | 1997-09-19 | 2003-08-05 | Promega Corporation | Thermostable luciferases and methods of production |
ATE375365T1 (de) | 1998-04-02 | 2007-10-15 | Genentech Inc | Antikörper varianten und fragmente davon |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
US7183387B1 (en) | 1999-01-15 | 2007-02-27 | Genentech, Inc. | Polypeptide variants with altered effector function |
BR0008758A (pt) | 1999-01-15 | 2001-12-04 | Genentech Inc | Variantes de polipeptìdeos parentais com funçãoefetora alterada, polipeptìdeos, composição ácidonucleico isolado, vetor, célula hospedeira,método para produzir uma variante depolipeptìdeo, método para o tratamento de umadesordem em mamìferos e método para produziruma região fc variante |
EP1197755A1 (en) | 2000-10-11 | 2002-04-17 | Pepscan Systems B.V. | Identification of protein binding sites |
EP1438400B1 (en) | 2001-10-01 | 2009-06-17 | Dyax Corp. | Multi-chain eukaryotic display vectors and uses thereof |
WO2003035842A2 (en) | 2001-10-24 | 2003-05-01 | Dyax Corporation | Hybridization control of sequence variation |
EP1513879B1 (en) | 2002-06-03 | 2018-08-22 | Genentech, Inc. | Synthetic antibody phage libraries |
WO2005044853A2 (en) | 2003-11-01 | 2005-05-19 | Genentech, Inc. | Anti-vegf antibodies |
ES2669510T3 (es) | 2004-09-23 | 2018-05-28 | Genentech, Inc. | Anticuerpos y conjugados modificados por ingeniería genética con cisteína |
US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
EA025871B9 (ru) | 2005-10-07 | 2017-08-31 | Экселиксис, Инк. | Ингибиторы mek и способы их применения |
TWI390034B (zh) * | 2006-04-06 | 2013-03-21 | Kyowa Hakko Kirin Co Ltd | Novel anti-CD98 antibody |
GB0615662D0 (en) * | 2006-08-07 | 2006-09-13 | Affitech As | Antibody |
CN103038255A (zh) * | 2010-03-26 | 2013-04-10 | 国立大学法人德岛大学 | 新抗cd98抗体及其用途 |
-
2012
- 2012-11-21 BR BR112014012590A patent/BR112014012590A8/pt not_active IP Right Cessation
- 2012-11-21 AU AU2012340623A patent/AU2012340623A1/en not_active Abandoned
- 2012-11-21 MX MX2014006272A patent/MX2014006272A/es unknown
- 2012-11-21 EP EP12795978.1A patent/EP2782935A1/en not_active Withdrawn
- 2012-11-21 RU RU2014124530/10A patent/RU2014124530A/ru not_active Application Discontinuation
- 2012-11-21 WO PCT/US2012/066347 patent/WO2013078377A1/en active Application Filing
- 2012-11-21 CA CA2856873A patent/CA2856873A1/en not_active Abandoned
- 2012-11-21 KR KR1020147016959A patent/KR20140125351A/ko not_active Application Discontinuation
- 2012-11-21 JP JP2014543574A patent/JP2015501639A/ja active Pending
- 2012-11-21 CN CN201280067876.7A patent/CN104302669A/zh active Pending
- 2012-11-21 SG SG11201402619VA patent/SG11201402619VA/en unknown
-
2014
- 2014-05-22 IL IL232755A patent/IL232755A0/en unknown
- 2014-05-22 ZA ZA2014/03760A patent/ZA201403760B/en unknown
- 2014-05-23 PH PH12014501164A patent/PH12014501164A1/en unknown
-
2015
- 2015-03-31 HK HK15103289.7A patent/HK1202877A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
WO2013078377A1 (en) | 2013-05-30 |
PH12014501164A1 (en) | 2014-10-20 |
HK1202877A1 (en) | 2015-10-09 |
CA2856873A1 (en) | 2013-05-30 |
WO2013078377A9 (en) | 2013-08-08 |
JP2015501639A (ja) | 2015-01-19 |
SG11201402619VA (en) | 2014-10-30 |
BR112014012590A2 (pt) | 2017-06-20 |
IL232755A0 (en) | 2014-07-31 |
AU2012340623A1 (en) | 2014-07-17 |
NZ626513A (en) | 2017-02-24 |
ZA201403760B (en) | 2017-09-27 |
EP2782935A1 (en) | 2014-10-01 |
CN104302669A (zh) | 2015-01-21 |
KR20140125351A (ko) | 2014-10-28 |
RU2014124530A (ru) | 2015-12-27 |
BR112014012590A8 (pt) | 2017-12-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2014006272A (es) | Anticuerpos anti-cd98 y metodos de uso de los mismos. | |
US10208120B2 (en) | Anti-FGFR2/3 antibodies and methods using same | |
US20150231240A1 (en) | Anti-c16orf54 antibodies and methods of use thereof | |
JP2021120382A (ja) | 部位特異的抗体コンジュゲーション方法および組成物 | |
CN104710532B (zh) | 人源化的抗-β7拮抗剂及其应用 | |
JP5955828B2 (ja) | 抗vegf抗体 | |
KR101541550B1 (ko) | 항체 및 면역접합체 및 이들의 용도 | |
CN108383909B (zh) | 抗sez6抗体及使用方法 | |
AU2006210837B2 (en) | Anti-EphB2 antibodies and methods using same | |
JP6942633B2 (ja) | 抗体の増強された有効性のための普遍的グリコフォームに関する組成物および方法 | |
JP5710487B2 (ja) | 抗notch2抗体および使用方法 | |
KR102630294B1 (ko) | 암 마커 및 이를 사용하는 방법 | |
BRPI0806403A2 (pt) | anticorpo anti-robo4, usode um anticorpo e método de obtenção de imagem | |
CN101437852A (zh) | 抗tat226抗体和免疫偶联物 | |
AU2007243132B2 (en) | Anti-EphrinB2 antibodies and methods using same | |
WO2015161247A1 (en) | Humanized anti-c16orf54 antibodies and methods of use thereof | |
TW201511770A (zh) | 診斷及治療肝癌之組合物及方法 | |
EP3601347B1 (en) | Compositions and methods for detecting and treating prostate cancer using progastrin binding molecule | |
BRPI0707047A2 (pt) | anticorpo produzido por hibridoma, anticorpos isolados, composição farmacêutica polinucleotìdeo, vetor, célula hospedeira, método para produção de um anticorpo, método para reduzir ou inibir a angiogênese e método pata aumentar a eficácia de um agente anti-angiogênico | |
EP3602060B1 (en) | Compositions and methods for treating lung cancer | |
JP2021512613A (ja) | 二重特異性抗原結合分子及びその使用方法 | |
CN111194222A (zh) | 与xCT抗体相关的组合物和方法 | |
NZ626513B2 (en) | Anti-cd98 antibodies and methods of use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
HC | Change of company name or juridical status |
Owner name: GELESIS, LLC |